Gastrointestinal hormone can decrease liver fat levels

According to a clinical study, published inThe Lancet, a variant of hormone FGF19 can reduce the liver fat levels of patients with non-alcoholic fatty liver disease and non-alcoholic steatohepatitis.Science Daily
Source: Society for Endocrinology - Category: Endocrinology Source Type: news

Related Links:

This article is protected by copyright. All rights reserved.
Source: Journal of Digestive Diseases - Category: Gastroenterology Authors: Tags: Guidelines Source Type: research
Excessive hepatic fat is associated with increased metabolic risk factors, production of inflammatory factors, and oxidative stress. High protein intake might trigger an increased hepatic lipid oxidation throu...
Source: Trials - Category: General Medicine Authors: Tags: Study protocol Source Type: research
ConclusionsThis study provides evidence for the role of PNPLA3 as a determinant of portal NAFLD localization and severity of portal fibrosis in children and adolescents, the risk variant being associated with an impaired hepatic retinol metabolism.This article is protected by copyright. All rights reserved.
Source: Liver International - Category: Gastroenterology Authors: Tags: Original Article Source Type: research
ConclusionsCurcumin is effective in lowering LDL-C, triglycerides, FBS, HOMA-IR, weight, and AST levels in NAFLD patients, and it is well tolerated. Further RCTs are required to confirm our findings.
Source: Hepatology International - Category: Infectious Diseases Source Type: research
This study will be conducted as a randomized, double-blind, placebo-controlled clinical trial for 12 weeks to receive daily β-CX 6 mg supplementation combined with a HPD on levels of metabolic factors, β-CX, glycemic and lipid profiles, inflammatory factors, adipocytokines, and body composition. Ninety-two eligible patients, aged 18–60 years, of both genders, who are obese and overweight (body mass index [BMI] 25– 40 kg/m2) will be randomly assigned to four groups as follow: HPD  + placebo; normal protein diet + β-CX (NPD + β-CX); HPD + &be...
Source: Trials - Category: Research Source Type: clinical trials
(Natural News) It is a little-known fact that even teetotalers can end up with liver disease. In fact, the most common form of this type of disease in the United States – non-alcoholic fatty liver disease (NAFLD) – affects close to 100 million people and can affect even those who drink little or no alcohol....
Source: - Category: Consumer Health News Source Type: news
Publication date: Available online 14 November 2018Source: Advances in Biological RegulationAuthor(s): Mariana Nikolova-KarakashianAbstractSphingolipids are class of metabolically distinct lipids that play structural and signaling functions in all organisms. Sphingolipid metabolism is deregulated during various diseases such as cancer, neurological and immune disorders, and metabolic syndrome. With the advancement of sphingo-lipidomics and sphingo-genomics, an understanding of the specific roles of ceramide, the quintessential bioactive sphingolipid, in fatty liver disease has taken shape. Two major pathways for ceramide g...
Source: Advances in Biological Regulation - Category: Biology Source Type: research
(University of Colorado Anschutz Medical Campus) Infant gut microbes altered by their mother's obesity can cause inflammation and other major changes within the baby, increasing the risk of obesity and non-alcoholic fatty liver disease later in life, according to researchers at the University of Colorado Anschutz Medical Campus.
Source: EurekAlert! - Biology - Category: Biology Source Type: news
Bariatric surgery is currently the more efficient technique to treat severe obesity. The two surgical procedures most commonly performed in the world are sleeve gastrectomy (SG) and Roux-en-Y gastric bypass (RYGB), because they induce remission or amelioration of obesity-related comorbidities in a majority of cases with an acceptable rate of complications. Notably, numerous studies have shown that these procedures improve non-alcoholic fatty liver diseases (NAFLD) whose prevalence is particularly high in obese patients and thus in candidates for bariatric surgery, reaching 86% on per-operative liver biopsies [1].
Source: Surgery for Obesity and Related Diseases - Category: Surgery Authors: Tags: Original articles Source Type: research
ConclusionsA weight reduction program can prevent cirrhosis and HCC occurrences, and dominates all other treatment options. Pioglitazone and vitamin E demonstrated a trend towards decreasing the number of cirrhosis and HCC cases.
Source: PharmacoEconomics - Category: Health Management Source Type: research
More News: Alcoholism | Endocrinology | Fatty Liver Disease (FLD) | Gastroenterology | Hormones | Liver | Liver Disease | Non-alcoholic Fatty Liver Diseases (NAFLD) | Science | Study | Urology & Nephrology